Developing a Point-of-Care Device for the Diagnosis of Sickle Cell Disease in Low Resource Settings

Period of Performance: 06/01/2016 - 09/01/2016


Phase 1 SBIR

Recipient Firm

Rockland Immunochemicals, Inc.
Pottstown, PA 19464
Principal Investigator


DESCRIPTION (provided by applicant):. Hemoglobinopathies are the most common monogenic diseases with approximately 7% of the world's population being carriers. Sickle cell disease (SCD) and thalassemia are primarily hemoglobin disorders. The current SCD diagnostic methods require expensive equipment and are performed by highly trained laboratory technologists. Presently there are no simple and inexpensive screening tests that can differentiate patients with sickle cell trait (HbAS) from sickle cell disease conditions (HbSS, HbSC and HbS ss-thalassemias). The goal of this project is to develop antibody- based lateral flow POC device that will allow efficiently, inexpensively and rapidly diagnose a patient with SCD. In Phase I, hemoglobin isoform-specific antibodies will be developed and lateral flow POC device prototypes will be formulated. In Phase II, POC device will be optimized, produced in a large scale and undergo extensive field hospital tests.